The optimal severe acute respiratory syndrome coronavirus 2 vaccine strategy for patients with a history of multisystem inflammatory syndrome in children (MIS-C) is unclear. We performed an international survey (32 countries) and found substantial variations in vaccine policies. Respondents did not report relapses of MIS-C or other severe inflammatory side effects after severe acute respiratory syndrome coronavirus 2 vaccination in 273 patients with a history of MIS-C.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, MIS-C, adverse events,
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, MIS-C, adverse events,